IL148782A0 - Drugs for the treatment of malignant tumours - Google Patents

Drugs for the treatment of malignant tumours

Info

Publication number
IL148782A0
IL148782A0 IL14878200A IL14878200A IL148782A0 IL 148782 A0 IL148782 A0 IL 148782A0 IL 14878200 A IL14878200 A IL 14878200A IL 14878200 A IL14878200 A IL 14878200A IL 148782 A0 IL148782 A0 IL 148782A0
Authority
IL
Israel
Prior art keywords
treatment
drugs
malignant tumours
compounds
formula
Prior art date
Application number
IL14878200A
Other languages
English (en)
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9903838A external-priority patent/SE9903838D0/xx
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of IL148782A0 publication Critical patent/IL148782A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL14878200A 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours IL148782A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16140799P 1999-10-25 1999-10-25
SE9903838A SE9903838D0 (sv) 1999-10-25 1999-10-25 Novel compounds
US21281600P 2000-06-21 2000-06-21
SE0002320A SE0002320D0 (sv) 1999-10-25 2000-06-21 Malignant tumors
PCT/SE2000/002055 WO2001030758A1 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours

Publications (1)

Publication Number Publication Date
IL148782A0 true IL148782A0 (en) 2002-09-12

Family

ID=27484521

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14878200A IL148782A0 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours
IL148782A IL148782A (en) 1999-10-25 2002-03-20 Drugs for the treatment of malignant tissues

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL148782A IL148782A (en) 1999-10-25 2002-03-20 Drugs for the treatment of malignant tissues

Country Status (21)

Country Link
EP (1) EP1224172B1 (no)
JP (1) JP3950337B2 (no)
KR (2) KR100674160B1 (no)
AT (1) ATE358668T1 (no)
AU (1) AU775057B2 (no)
CA (1) CA2386775C (no)
CZ (1) CZ298534B6 (no)
DE (1) DE60034240T2 (no)
DK (1) DK1224172T3 (no)
EE (1) EE200200207A (no)
ES (1) ES2280258T3 (no)
HK (1) HK1049830A1 (no)
HR (1) HRP20020353A2 (no)
HU (1) HU229072B1 (no)
IL (2) IL148782A0 (no)
IS (1) IS2750B (no)
NO (1) NO323320B1 (no)
NZ (1) NZ518296A (no)
SE (1) SE0002320D0 (no)
UA (1) UA73748C2 (no)
WO (1) WO2001030758A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
EP2489659B1 (en) 2004-06-24 2017-12-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
CA2625287C (en) 2005-10-19 2016-07-26 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
ES2790700T3 (es) 2005-12-28 2020-10-28 Vertex Pharma Composiciones farmacéuticas de la forma amorfa de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolin-3-carboxamida
ZA200810790B (en) 2006-06-12 2010-03-31 Teva Pharma Stable laquinimod preparations
KR100916160B1 (ko) * 2007-02-21 2009-09-08 (주)바이오버드 약제학적 항암 조성물
EP2065380A1 (en) * 2007-08-22 2009-06-03 F.Hoffmann-La Roche Ag Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer
EP2234485B1 (en) 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
KR20160079147A (ko) 2008-09-03 2016-07-05 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
BRPI1011506B8 (pt) 2009-03-20 2021-05-25 Vertex Pharma processo para a fabricação de moduladores de regulador de condutância de transmembrana de fibrose cística
CN103153959A (zh) 2010-10-14 2013-06-12 伊姆纳尔公司 作为AhR活化剂的1，2-二氢-4-羟基-2-氧代-喹啉-3-甲酰苯胺类
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2537517A1 (en) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
CN104470518A (zh) 2012-02-27 2015-03-25 沃泰克斯药物股份有限公司 药物组合物及其施用
KR20150091077A (ko) * 2012-11-07 2015-08-07 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드의 아민염
AU2014236232A1 (en) 2013-03-14 2015-11-05 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
CA2961978C (en) 2014-09-23 2023-03-14 Active Biotech Ab Quinoline carboxamides for use in the treatment of multiple myeloma
WO2016057730A1 (en) 2014-10-07 2016-04-14 Strohmeier Mark Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
PL3180005T3 (pl) 2014-11-19 2018-06-29 Active Biotech Ab Chinolinokarboksyamidy do stosowania w leczeniu białaczki
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
IL295780A (en) 2020-03-03 2022-10-01 Active Biotech Ab Tesquinimov or a pharmaceutically acceptable salt thereof for use in combination therapy
EP4153576A4 (en) * 2020-05-21 2024-06-19 Stemsynergy Therapeutics Inc NOTCH INHIBITORS AND USES THEREOF
CA3204120A1 (en) 2021-01-18 2022-07-21 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
AU2022281056A1 (en) 2021-05-25 2023-11-30 Active Biotech Ab A plurality of tasquinimod particles and use thereof
CA3221689A1 (en) 2021-07-02 2023-01-05 Hans Wannman A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product
AU2022341311A1 (en) * 2021-09-13 2024-03-21 Eli Lilly And Company Ahr agonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
GB9404378D0 (en) * 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
GB2290786A (en) * 1994-06-30 1996-01-10 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives

Also Published As

Publication number Publication date
ES2280258T3 (es) 2007-09-16
IS2750B (is) 2011-08-15
KR100674160B1 (ko) 2007-01-24
EP1224172B1 (en) 2007-04-04
NO323320B1 (no) 2007-03-12
ATE358668T1 (de) 2007-04-15
NO20021932L (no) 2002-06-21
EP1224172A1 (en) 2002-07-24
NZ518296A (en) 2003-06-30
KR100597938B1 (ko) 2006-07-06
CA2386775C (en) 2004-07-13
HRP20020353A2 (en) 2005-10-31
IS6329A (is) 2002-04-02
HK1049830A1 (zh) 2003-05-30
DE60034240T2 (de) 2007-12-20
WO2001030758A1 (en) 2001-05-03
KR20060054496A (ko) 2006-05-22
CZ298534B6 (cs) 2007-10-31
JP3950337B2 (ja) 2007-08-01
DK1224172T3 (da) 2007-08-13
AU1185101A (en) 2001-05-08
EE200200207A (et) 2003-06-16
IL148782A (en) 2007-05-15
HUP0203238A2 (hu) 2003-01-28
NO20021932D0 (no) 2002-04-24
HU229072B1 (en) 2013-07-29
KR20020043646A (ko) 2002-06-10
DE60034240D1 (de) 2007-05-16
HUP0203238A3 (en) 2003-05-28
CZ20021293A3 (cs) 2002-07-17
UA73748C2 (en) 2005-09-15
JP2003512454A (ja) 2003-04-02
AU775057B2 (en) 2004-07-15
CA2386775A1 (en) 2001-05-03
SE0002320D0 (sv) 2000-06-21

Similar Documents

Publication Publication Date Title
YU23202A (sh) Lekovi za tretman malignih tumora
IL148782A0 (en) Drugs for the treatment of malignant tumours
PL367682A1 (en) Dolastatin 10 derivatives
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
SE9904505D0 (sv) Novel compounds
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
MXPA04001500A (es) Compuestos que tienen un efecto sobre la glucocinasa.
HK1053115A1 (en) Quinazoline derivatives for the treatment of tumours.
MY136430A (en) N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation
WO2005115470A3 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-­CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS
PL1727817T3 (pl) Pochodne azabicyklooktan-3-onu i ich zastosowanie
MXPA04004606A (es) Venenos de topoisomerasa solubilizados.
GB0109122D0 (en) Novel compounds
ZA200110540B (en) Novel diphenyl-piperidine derivate.
PL342614A1 (en) Anticarcinogenic drugs
JO2390B1 (en) Diphenylcarboxamides act as lipid-lowering agents
AU2002352708A1 (en) Cytotoxic agents
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
TW200634002A (en) Chemical compounds
GB9907571D0 (en) Compounds
NO20030420L (no) Medikament for immunoterapi av maligne tumorer
SE0004827D0 (sv) Therapeutic compounds
MXPA05010135A (es) Nuevos derivados de oxazol, procedimiento para su fabricacion y uso como agentes farmaceuticos.
WO2002098399A3 (en) Cancer treatment method and compositions comprising compounds of the ginger family

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed